Litigation Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Docket	1:18-cv-00192-CFC-CJB	Date Filed	2018-02-01
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To	Christopher J. Burke
Patents	10,004,746; 10,016,435; 10,106,548; 10,125,140; 10,294,231; 10,294,232; 7,514,444; 8,008,309; 8,476,284; 8,497,277; 8,697,711; 8,735,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 8,999,999; 9,125,889; 9,181,257; 9,296,753; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604; 9,801,881; 9,801,883
Link to Docket	External link to docket

Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-02-01	1		United States Patent Nos. 8,008,309 (“the ’309 Patent”); 7,514,444 (“the ’444 Patent”); 8,697,711 (“…(“the ’711 Patent”); 8,735,403 (“the ’403 Patent”); 8,957,079 (“the ’079 Patent”); 9,181,257 (“the ’257…’257 Patent”); 8,754,091 (“the ’091 Patent”); 8,497,277 (“the ’277 Patent”); 8,952,015 (“the ’015 Patent…37 PageID #: 2 Patent”); 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 (“the… 1. This action for patent infringement, brought pursuant to the patent laws of the United States	External link to document
2018-02-01	104		B2 ;9,801,881 B2 ;9,801,883 B2 ;10,125,140 B1 ;10,106,548 B2. (fms) (Entered: 02/14/2019) 14 February… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,296,753 B2 ;…February 2018 1:18-cv-00192-CFC-CJB 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2018-02-01	128	Answer to Counterclaim	Admitted. 17. U.S. Patent No. 10,106,548 (“the ’548 Patent”), on its face, is titled “Crystalline…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the	External link to document

Litigation summary and analysis for: Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Last updated: June 30, 2026

Pharmacyclics LLC v. Cipla Limited (C.D. Cal. 1:18-cv-00192-CFC-CJB): Litigation Summary, Patent Issues, and Market Impact

What happened in Pharmacyclics LLC v. Cipla Limited (1:18-cv-00192-CFC-CJB)?

Pharmacyclics LLC sued Cipla Ltd. in the U.S. District Court for the District of Delaware under case number 1:18-cv-00192-CFC-CJB. The dispute is a patent infringement action tied to Cipla’s efforts to market an accused product that implicates Pharmacyclics’ patent estate around ibrutinib (Janssen/AbbVie Pharmacyclics franchise).

Core posture. This litigation tracks the typical U.S. generic entry playbook: an innovator asserts Orange Book-listed patents against a proposed generic manufacturer, and the parties litigate infringement and validity, often leading to one of three outcomes: adjudicated noninfringement, invalidity, or a settlement that drives a licensed launch at a defined time.

Outcome status. No complete, case-specific resolution data is available in the provided prompt. Without verified docket disposition, claim construction outcomes, or settlement terms, a definitive end-state cannot be stated.

Which patents were asserted in the case?

Insufficient information in the provided prompt to identify the asserted U.S. patents, claim numbers, or Orange Book identifiers for the specific filing.

Under 35 U.S.C. § 271(e)(2), innovator complaints typically reference a set of patents listed for the relevant NDA or ANDA entry, including:

• composition and formulation patents,
• manufacturing or process patents,
• method-of-use patents,
• and sometimes patents directed to polymorphs, salts, or stability.

A reliable litigation analysis requires the exact asserted patent list.

What is the litigation timeline for 1:18-cv-00192-CFC-CJB?

Insufficient information in the provided prompt to reconstruct a fact-accurate timeline.

A proper timeline would normally include:

• complaint filing date,
• service date,
• answer and defenses (invalidity, noninfringement, unenforceability, prosecution history estoppel),
• PTAB activity (if any) that overlaps claim scopes,
• claim construction schedule and Markman hearing,
• summary judgment motions,
• trial dates and outcomes,
• and any settlement or consent judgment.

No verifiable dates are included in the prompt.

What was the legal basis for infringement in Pharmacyclics v. Cipla?

The governing statute in Hatch-Waxman follow-on litigation is usually 35 U.S.C. § 271(e)(2) (infringement based on filing an ANDA or similar regulatory submission), paired with claims that the proposed product would infringe if manufactured and sold.

Common defense themes in this drug-class and product-family category include:

• noninfringement based on differences in the accused composition or formulation parameters,
• invalidity for lack of novelty or obviousness,
• anticipation by earlier disclosures or obviousness combinations,
• enablement or written description issues,
• and inequitable conduct or unenforceability theories if asserted.

What were the key claim-construction and infringement issues likely at stake?

Not determinable from the provided prompt.

Claim-construction disputes in Pharmacyclics-style patent estates for ibrutinib products typically focus on:

• whether the asserted claims are directed to a specific formulation feature (e.g., release characteristics, particle size, excipient system, stability parameters),
• whether an accused ANDA product meets a numeric limitation (where the patents include thresholds),
• whether the asserted method claims are triggered by proposed labeling or instructions,
• and whether the accused manufacturing method falls within process claims.

A credible analysis must map the claim language to the accused product specifications or manufacturing disclosures, which are not provided.

How did the case affect biosimilar or generic entry risk for this franchise?

Biosimilar angle. 1:18-cv-00192-CFC-CJB is not a biosimilar dispute in the usual sense. The actor set (Pharmacyclics and Cipla) and the typical Pharmacyclics patent estate for ibrutinib align with small-molecule generic and/or ANDA litigation, not biologics. A biosimilar risk assessment cannot be supported without explicit confirmation that the accused product is a biologic.

Generic entry risk angle. In small-molecule ANDA disputes, the litigation’s practical impact is:

• it can block or delay approval or commercial launch if a court enjoins entry,
• it can result in a licensed launch with design-around constraints,
• or it can clear the way if the patents are held invalid or not infringed.

Because resolution and any settlement terms are not provided, the direction and magnitude of market impact cannot be quantified.

What is the Orange Book status and how does it tie to this litigation?

The prompt does not include the relevant NDA/ANDA number(s) or Orange Book listing identifiers for the Pharmacyclics patents at issue.

In these disputes, Orange Book listings usually determine:

• which patents can be asserted under § 271(e)(2),
• which are “carved out” by dismissal or noninfringement findings,
• and whether the case involves Paragraph IV certifications (often required for an ANDA to challenge listed patents).

Without the Orange Book listing set and certification type, an accurate Orange Book linkage is not possible.

What Paragraph IV challenges or FDA certification issues were litigated?

Not specified in the provided prompt.

In typical ANDA litigation:

• the ANDA filer certifies to each Orange Book patent (Paragraph I, II, III, IV, or V),
• the Paragraph IV certification triggers infringement litigation. A credible analysis depends on the specific certification, the patent numbers, and the timing relative to any FDA approval.

Did the parties reach a settlement or consent judgment?

No settlement or consent judgment details are included in the provided prompt.

A settlement analysis would require:

• settlement date,
• effective terms on launch dates,
• covenant structure (e.g., early entry if a court invalidates claims or if FDA approval timelines shift),
• and any royalty or license terms (if present).

How does Cipla’s litigation posture compare with other generic challengers of Pharmacyclics patents?

Not determinable from the provided prompt.

Comparable assessment requires:

• whether Cipla is a first filer or has co-filers,
• whether other ANDA filers settled or litigated to judgment,
• and whether claims asserted against Cipla differ materially from those asserted against others.

What is the strength of the asserted Pharmacyclics patent estate in this case?

Not possible to assess without the asserted patent list and at least one of: court holdings, PTAB outcomes, or claim construction findings.

A patent-strength framework for this sort of litigation would typically evaluate:

• claim scope clarity and objective boundaries,
• prior art density and anticipation risk,
• prosecution history constraints,
• and whether enforcement has held up in parallel cases.

What manufacturing and IP barriers typically arise in ibrutinib formulation disputes?

Specific barriers are not established from the provided prompt.

For small-molecule Rx generics, barriers often include:

• proving equivalence for dissolution, stability, or bioavailability (where patents claim particular formulation properties),
• design-around constraints if patents claim specific excipient systems or processing conditions,
• and compliance with test methods used to establish claim satisfaction.

Any deeper technical analysis requires the accused product attributes and asserted claim limitations.

Revenue exposure: what commercial impact is tied to this specific case?

Cannot be quantified from the provided prompt.

A credible revenue-exposure estimate requires:

• the relevant product’s sales window,
• ANDA approval and launch status,
• any court injunction duration or settlement-driven launch date,
• and the number and strength of asserted patents.

Key takeaways on Pharmacyclics v. Cipla (1:18-cv-00192-CFC-CJB)

• The case is a Pharmacyclics patent infringement dispute involving Cipla in the U.S. federal court system under 1:18-cv-00192-CFC-CJB.
• The prompt does not provide the asserted patent numbers, claim scopes, or the case disposition needed to produce a case-grade litigation outcome analysis.
• A complete litigation summary for this docket requires verified records for the asserted Orange Book patents, FDA certification posture, claim construction outcomes, and final disposition.

FAQs

1. What patents are generally asserted by Pharmacyclics in ANDA cases involving ibrutinib?
2. How do courts evaluate infringement for formulation patents in generic ANDA litigation?
3. What are the typical legal defenses used by generic filers in § 271(e)(2) patent suits?
4. How does Orange Book patent listing affect what claims can be asserted in a Hatch-Waxman case?
5. What settlement structures are common in innovator vs. generic patent litigations for small-molecule oncology drugs?

References

1. U.S. District Court docket for Pharmacyclics LLC v. Cipla Limited, 1:18-cv-00192-CFC-CJB.